Sponsors (2)
The bill seeks to lower drug prices broadly—especially for federal program enrollees and many patients—by tying U.S. pricing to lower international benchmarks, but it risks reduced drug availability, shifted costs to employers/insurers or patients, and implementation/legal challenges that could blunt benefits.
Medicare, Medicaid, CHIP and other federal program enrollees would pay no more than an annual international reference price for covered outpatient and inpatient drugs, lowering out‑of‑pocket costs for millions of beneficiaries.
Using the lowest price among 12 peer countries as a reference could substantially reduce U.S. drug list prices overall, reducing costs for many patients and public programs.
Uninsured and privately insured individuals could buy covered drugs at the reference price because manufacturers must offer that price to all individuals, increasing affordability beyond federal enrollees.
Patients with chronic conditions could face reduced access or delayed access to some drugs if manufacturers limit supply or delay U.S. launches in response to lower reference prices.
Employers and insurers (and therefore workers and families) could see higher premiums or narrower drug coverage if payers and manufacturers shift costs or change negotiation strategies to offset revenue effects.
Very large civil penalties (five times the price difference) create substantial liability risk for manufacturers that could be passed on to patients via other prices or reduce industry investment in R&D if enforcement undermines revenue predictability.
Based on analysis of 2 sections of legislative text.
Caps retail list prices for drugs sold to federal program enrollees at an HHS annual reference price based on certain foreign prices or other factors, with heavy penalties for noncompliance.
Introduced May 14, 2025 by Debbie Dingell · Last progress May 14, 2025
Requires the Secretary of Health and Human Services to set an annual reference price for every prescription drug and stops retail list prices charged to enrollees or beneficiaries in major federal health programs from exceeding that reference price. Reference prices are set as the lowest listed retail price among a specified group of foreign countries when at least three comparable prices exist, or otherwise by a value-based determination using factors like therapeutic benefit, access, and R&D costs. Manufacturers must offer the drug at the reference price to all individuals, and large civil penalties (five times the difference) apply for noncompliance, with collected penalties transferred to NIH for drug research.